Positive SIRONA Study Results Highlight Sirolimus-Coated Balloons as Effective Alternative to Paclitaxel for PAD Treatment

Concept Medical Inc., a global leader in innovative drug delivery technologies, is proud to report positive results from the SIRONA (Head-to-Head...

January 08, 2025 | Wednesday | News
Briggs Morrison, M.D., Joins CRISPR Therapeutics to Propel Innovation in Gene Editing

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced it ...

January 08, 2025 | Wednesday | News
GSK Secures FDA Breakthrough Therapy Designation for GSK5764227 in Relapsed Osteosarcoma

GSK plc (LSE/NYSE: GSK) announced  that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK&rsq...

January 08, 2025 | Wednesday | News
Norgine Files Marketing Authorization for Eflornithine in High-Risk Neuroblastoma with EMA

Norgine announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neurobl...

January 07, 2025 | Tuesday | News
ADC Therapeutics Completes Enrollment in Phase 3 LOTIS-5 Trial of ZYNLONTA® (Loncastuximab Tesirine) for Relapsed or Refractory DLBCL

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs),  announced the co...

December 31, 2024 | Tuesday | News
Novartis Reports Positive Phase III STEER Trial Results for SMA Gene Therapy

The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal...

December 30, 2024 | Monday | News
Johnson & Johnson Secures EC Approval for Amivantamab-Lazertinib Combo as First-Line Treatment for EGFR-Mutated NSCLC

  Janssen-Cilag International NV, a Johnson & Johnson company,  announced the European Commission (EC) approval of RYBREVANT®▼ (amivan...

December 30, 2024 | Monday | News
AstraZeneca’s Tagrisso Approved in the EU for Locally Advanced, Unresectable EGFR-Mutated NSCLC

AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with locally advanced...

December 24, 2024 | Tuesday | News
Sanofi and SK bioscience Expand Collaboration to Develop Next-Generation Pneumococcal Vaccines for Global Impact

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and...

December 24, 2024 | Tuesday | News
FDA Approves ALYFTREK® (Vanzacaftor/Tezacaftor/Deutivacaftor) as Once-Daily Treatment for Cystic Fibrosis

 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (v...

December 21, 2024 | Saturday | News
Roche Reports Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson&rs...

December 20, 2024 | Friday | News
Valneva and Serum Institute of India Partner to Deliver Asia’s First Single-Shot Chikungunya Vaccine

  Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s...

December 19, 2024 | Thursday | News
Merck acquires HUB Organoids to transform drug development and advance research sustainability.

HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organ...

December 19, 2024 | Thursday | News
Catalent’s $16.5 Billion Acquisition by Novo Holdings Sets the Stage for Transforming Global Healthcare

Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S...

December 19, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close